Based on this finding and background knowledge on CD32 receptors, we have in a separate effort isolated a CD32b-specific antibody, BI-1206.8 This antibody is currently tested in two phase I/II clinical trials (NCT02933320 and NCT03571568) on CD32b-positive B-cell lymphomas and leukemias. The gene discussed is CACNA1A; the disease is B-cell non-Hodgkin lymphoma.